Table 1.
Sociodemographic and clinical characteristics at baseline in the overall STAR (Schizophrenia Trial of Aripiprazole) study population and group of patients included in this analysis
| Analysis population (n = 351)a | Randomized population (n = 555)b | |
|---|---|---|
| Gender [n (%) of male] | 220 (62.7%) | 332 (59.8%) |
| Age (years) | ||
| Mean ± standard deviation (SD) | 38.6 ± 11.4 | 38.5 ± 10.9 |
| Median | 37.0 | 37.0 |
| Baseline weight (kg) | ||
| Mean ± SD | 80.2 ± 17.0 | 80.7 ± 17.2 |
| Median | 78.2 | 79.0 |
| Schizophrenia subtype [n (%)] | ||
| Disorganized | 41 (11.7%) | 56 (10.1%) |
| Catatonic | 6 (1.7%) | 7 (1.3%) |
| Paranoid | 222 (63.3%) | 361 (65.0%) |
| Residual | 44 (12.5%) | 67 (12.1%) |
| Undifferentiated | 38 (10.8%) | 64 (11.5%) |
| Allocated treatment [n (%)] | ||
| Aripiprazole | 179 (51.0%) | 284 (51.2%) |
| Standard of care | 172 (49.0%) | 271 (48.8%) |
a
The analysis population was defined as all patients with at least one post‐baseline assessment of both Quality of Life Scale (QLS) and the Clinical Global Impressions of Severity (CGI‐S) (anchor criterion).
b
Adapted from Kerwin et al. (2007).